Dechra Pharmaceuticals PLC Annual Financial Report (3235M)
20 September 2021 - 8:42PM
UK Regulatory
TIDMDPH
RNS Number : 3235M
Dechra Pharmaceuticals PLC
20 September 2021
Monday, 20 September 2021
Dechra (R) Pharmaceuticals PLC
(the Company)
Annual Financial Report
The Company announced its Preliminary Results on 6 September
2021 in accordance with the financial reporting obligations of the
Disclosure and Transparency Rules.
Copies of the Annual Report and Accounts for the year ended 30
June 2021, Notice of Annual General Meeting and Proxy Form have now
been mailed to shareholders.
In accordance with Listing Rule 9.6.1 a copy of the Annual
Financial Report and Notice of Meeting has been submitted to the
FCA document viewing facility
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The Annual Report and Accounts, Notice of Annual General Meeting
and information relating to the voting rights of Shareholders (as
required by section 311A of the Companies Act 2006) are available
to view on the Company's website www.dechra.com . Further copies of
the Annual Report and Accounts are available from the Company's
registered office at:
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA
Enquiries:
Melanie Hall, Company Secretary
Dechra Pharmaceuticals PLC
Tel: +44 (0) 1606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSSESFSSEFSELU
(END) Dow Jones Newswires
September 20, 2021 06:42 ET (10:42 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024